Nicholas D. Socci

Memorial Sloan Kettering Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

110h-index64.5kcitations871works2.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(168), Sarcoma Diagnosis and Treatment(113), Cancer-related molecular mechanisms research(84), Lung Cancer Treatments and Mutations(70), Immunotherapy and Immune Responses(60)

Publications821 total

A transposase-derived gene required for human brain development

Science Advances·2026Open Access

Supplementary Tables S1-S2 from Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology

2025Open Access

Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

2025Open Access

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

2025Open Access

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

2025Open Access

page 1 of 42Next →

Frequent Co-authors

Agnès Viale(16), Barry S. Taylor(8), Marc Ladanyi(7), Nikolaus Schultz(6), Chris Sander(6), Michael F. Berger(6), David B. Solit(6), Robert G. Maki(5), Cristina R. Antonescu(5), Lorenz Studer(5), Adriana Heguy(4), Howard I. Scher(4), José N. Onuchic(4), Ross L. Levine(4), Philip Jonsson(4), Ahmet Zehir(4), Scott W. Lowe(4), Alex Lash(3), Charles L. Sawyers(3), Peter G. Wolynes(3)